| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6034267 | GALDERMA LABS LP | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
Mar, 2016
(8 years ago) | |
Metvixia is owned by Galderma Labs Lp.
Metvixia contains Methyl Aminolevulinate Hydrochloride.
Metvixia has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Metvixia are:
- US6034267
Metvixia was authorised for market use on 27 July, 2004.
Metvixia is available in cream;topical dosage forms.
Metvixia can be used as treatment of actinic keratoses by photodynamic therapy.
The generics of Metvixia are possible to be released after 08 March, 2016.
Drugs and Companies using METHYL AMINOLEVULINATE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 July, 2004
Treatment: Treatment of actinic keratoses by photodynamic therapy
Dosage: CREAM;TOPICAL
More Information on Dosage
METVIXIA family patents
